Carlyle Group Inc. Amends Soleno Therapeutics Stake
Ticker: CGABL · Form: SC 13D/A · Filed: Sep 10, 2024 · CIK: 1527166
| Field | Detail |
|---|---|
| Company | Carlyle Group Inc. (CGABL) |
| Form Type | SC 13D/A |
| Filed Date | Sep 10, 2024 |
| Risk Level | medium |
| Pages | 10 |
| Reading Time | 12 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, sec-filing, investment-management
Related Tickers: SLNO
TL;DR
Carlyle Group Inc. updated its Soleno Therapeutics stake filing on 9/10/24.
AI Summary
Carlyle Group Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of Soleno Therapeutics Inc. as of September 10, 2024. The filing details the group members involved in this reporting entity. Carlyle Group Inc. is a significant investment management firm.
Why It Matters
This filing signals a potential shift in the ownership structure or investment strategy concerning Soleno Therapeutics Inc., which could impact its stock price and corporate governance.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership filings can indicate shifts in investor sentiment or strategic moves that may affect a company's stock.
Key Players & Entities
- Carlyle Group Inc. (company) — Filing entity
- Soleno Therapeutics Inc. (company) — Subject company
- ABINGWORTH BIOVENTURES VII LP (company) — Group member
- ABINGWORTH LLP (company) — Group member
- CARLYLE GENESIS UK LLC (company) — Group member
- CARLYLE HOLDINGS I GP INC. (company) — Group member
- CARLYLE HOLDINGS I GP SUB L.L.C. (company) — Group member
- CARLYLE HOLDINGS I L.P. (company) — Group member
- CARLYLE INVESTMENT MANAGEMENT L.L.C. (company) — Group member
- CG SUBSIDIARY HOLDINGS L.L.C. (company) — Group member
FAQ
What specific change in beneficial ownership is being reported by Carlyle Group Inc. for Soleno Therapeutics Inc.?
The filing is an amendment to a Schedule 13D, indicating a change in beneficial ownership, but the specific percentage or number of shares acquired or disposed of is not detailed in the provided text.
What is the filing date of this SC 13D/A amendment?
The filing date is September 10, 2024.
Who are the listed group members of Carlyle Group Inc. for this filing?
The listed group members include ABINGWORTH BIOVENTURES VII LP, ABINGWORTH LLP, CARLYLE GENESIS UK LLC, CARLYLE HOLDINGS I GP INC., CARLYLE HOLDINGS I GP SUB L.L.C., CARLYLE HOLDINGS I L.P., CARLYLE INVESTMENT MANAGEMENT L.L.C., CG SUBSIDIARY HOLDINGS L.L.C., and TC GROUP, L.L.C.
What is the primary business of Soleno Therapeutics Inc.?
Soleno Therapeutics Inc. is in the Electromedical & Electrotherapeutic Apparatus industry, with SIC code 3845.
What is the business address of Carlyle Group Inc.?
The business address of Carlyle Group Inc. is C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC 20004.
Filing Stats: 2,971 words · 12 min read · ~10 pages · Grade level 10.7 · Accepted 2024-09-10 18:30:26
Key Financial Figures
- $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
Filing Documents
- formsc13da.htm (SC 13D/A) — 291KB
- ex5.htm (EX-5) — 56KB
- ex5_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-035677.txt ( ) — 354KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : September 10, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings I GP Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I L.P. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group, L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director Carlyle Investment Management L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Abingworth LLP By: /s/ John Heard Name: John Heard Title: Authorized Signatory Abingworth Bioventures VII LP By: /s/ John Heard Name: John Heard Title: Authorized Signatory